Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of …
Biotechnology
BE, Mechelen [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 9.86 | 9.91 | 9.02 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 152.28 | 8.81 | 3.49 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 3.74 | 43.93 | 42.35 | |
| Cash | -3.27 | 53.99 | 55.82 | |
| Capex | 21.37 | -0.10 | -0.12 | |
| Free Cash Flow | -66.03 | -1.88 | -1.13 | |
| Revenue | -70.09 | 0.95 | -3.17 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -31.67 | 0.96 | 1.40 | |
| Operating Margin | 105.48 | -0.68 | 0.33 | |
| ROA | -42.79 | 0.02 | 0.04 | |
| ROE | -44.71 | 0.03 | 0.06 | |
| ROIC | 35.18 | -0.02 | -0.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of GLPGF is permitted for members.
5
Growth
The "Growth Entry" for the Focus of GLPGF is permitted for members.
6
Leverage & Liquidity